Enlivex, a Nasdaq-listed biotech company, is asking shareholders to authorize up to $800 million of financing tied to the RAIN crypto token — a deal that could dilute existing holders by as much as 951%. The financing is primarily a crypto-treasury transaction, with most proceeds earmarked for acquiring more RAIN tokens, other treasury purposes, and debt. Only a sliver — up to 5% of remaining USD proceeds after fees, expenses, and debt — would go to Enlivex's drug Allocetra.
The financing structure
Shareholders must approve two pieces: an initial $400 million placement and a separate $400 million option, totaling up to $800 million. The first tranche alone could represent roughly 396% to 475% of Enlivex's current outstanding shares — and that's after a 1-for-15 reverse split that reduced shares to about 16.83 million. The investor can choose to pay in RAIN tokens at $6 per ordinary share equivalent, or in USD, USDT, or USDC at $5 per share equivalent. If the optional second tranche is fully used under the cash payment method, total new share equivalents could reach 160 million, leaving existing holders at about 9.5% of the total.
Who is the buyer?
The public documents don't clearly identify the buyer. Enlivex's Form 6-K calls it 'Rain Foundation', but the agreement defines 'Token Factor Foundation' as the lead investor. The public purchaser signature block is left blank. That's unusual for a deal of this size. Without a named counterparty, shareholders are being asked to approve a massive dilution without knowing exactly who's on the other side.
What the money is for
RAIN tokens delivered at closing go straight to company treasury. Cash or stablecoin proceeds are earmarked for acquiring RAIN, other treasury purposes, transaction costs, and debt. Only after those costs and debt are covered can up to 5% of remaining USD proceeds fund Allocetra, Enlivex's drug candidate. This isn't a traditional biotech financing for R&D — it's a crypto-treasury play, more akin to what Strategy (formerly MicroStrategy) and Metaplanet have done with Bitcoin.
The RAIN token pricing
The RAIN token price for the transaction is set from CoinMarketCap's average closing price over the five business days before closing. That's a reference price, not a realizable cash value. If the token's market price drops between pricing and closing, the company could end up with less value than expected. The structure leaves existing shareholders exposed to crypto volatility without the upside of a direct token investment.
The shareholder vote is the next concrete step. The unresolved question: who is the actual investor behind the blank signature block? Until that's answered, the deal's legitimacy remains in doubt.
